Key result
Novel therapeutics targeting angiogenesis, including mesenchymal stem cells, exosomes, biomaterials, biological factors, and gene therapy, show potential for cardiac repair after acute myocardial infarction.
Why the study?
Despite surgery and medical treatment for AMI, dead cardiomyocytes do not regenerate and scar tissue has limited contractile ability, making blood flow restoration in the infarcted area important for myocardial repair.
Emerging therapies targeting angiogenesis, such as exosomes and biomaterials, offer promising future strategies for myocardial repair and preventing heart failure post-myocardial infarction.
Angiogenesis modulation after AMI may aid repair; leaves open optimal strategies pending prospective trials.
Acute myocardial infarction (AMI) remains the main cause of mortality worldwide. Despite surgery and medical treatment, the non-regeneration of dead cardiomyocytes and the limited contractile ability of scar tissue can lead to heart failure. Therefore, restoring blood flow in the infarcted area is important for the repair of myocardial injury. The objective of the present review was to summarize the factors influencing angiogenesis after AMI, and to describe the application of angiogenesis for cardiac repair. Collectively, this review may be helpful for relevant studies and to provide insight into future therapeutic applications in clinical practice.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a review in Acute myocardial infarction. Angiogenesis-targeted therapeutics (MSCs, exosomes, biomaterials, biological factors, gene therapy) was evaluated. Novel therapeutics targeting angiogenesis, including mesenchymal stem cells, exosomes, biomaterials, biological factors, and gene therapy, show potential for cardiac repair after acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: